Viral oncoapoptosis of human tumor cells

Gene Therapy

Volumn 10, Issue 17, 2003, Pages 1437-1445

  Aubert, M ^a   Blaho, J A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Carcinoma; Genetic therapy; Herpes simplex virus; Programmed cell death

Indexed keywords

PROTEIN P53; VIRUS DNA; VIRUS PROTEIN;

APOPTOSIS; CANCER CELL; CANCER CELL DESTRUCTION; CELL DEATH; CELL KILLING; CELL LINE; CELL TRANSFORMATION; CONTROLLED STUDY; DISEASE MODEL; DRUG DESIGN; ENVIRONMENTAL FACTOR; FEASIBILITY STUDY; FIBROBLAST; GENE THERAPY; GENETIC SUSCEPTIBILITY; HELA CELL; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN SYNTHESIS; PROTEIN TARGETING; REVIEW; TUMOR CELL; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION; WART VIRUS;

ANIMALS; APOPTOSIS; CELL LINE, TRANSFORMED; CELLS, CULTURED; DNA, VIRAL; FIBROBLASTS; GENE THERAPY; HELA CELLS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MICROSCOPY, PHASE-CONTRAST; SIMPLEXVIRUS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; VIRUS REPLICATION;

ANIMALIA; DNA VIRUSES; HUMAN PAPILLOMAVIRUS TYPES; SIMPLEXVIRUS;

EID: 0042526014     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302004     Document Type: Review

References (78)

1. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239-257.
2. Cryns V, Yuan J. Proteases to die for. Genes Dev 1998; 12: 1551-1570.
3. Salvesen GS, Dixit VM. Caspases: intracellular signaling by proteolysis. Cell 1997; 91: 443-446.
4. Green DA, Evan G. A matter of life and death. Cancer Cell 2002; 1: 19-30.
5. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000; 21: 485-495.
6. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331.
7. Prives C, Hall PA. The p53 pathway. J Pathol 1999; 187: 112-126.
8. Hainaut P et al. IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res 1998; 26: 205-213.
9. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 2000; 77: 81-137.
10. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-967.
11. Lowe SW et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266: 807-810.
12. Weinstein JN et al. An information-intensive approach to the molecular pharmacology of cancer. Science 1997; 275: 343-349.
13. Koyama AH, Fukumori T, Fujita M, Irie H, Adachi A. Physiological significance of apoptosis in animal virus infection. Microbes Infect 2000; 2: 1111-1117.
14. Aubert M, Blaho JA. Modulation of apoptosis during herpes simplex virus infection in human cells. Microbes Infect 2001; 3: 859-866.
15. Aubert M, O'Toole J, Blaho JA. Induction and prevention of apoptosis in human HEp-2 cells by herpes simplex virus type 1. J Virol 1999; 73: 10359-10370.
16. Honess RW, Roizman B. Regulation of herpesvirus macromolecular synthesis. I. Cascade regulation of the synthesis of three groups of viral proteins. J Virol 1974; 14: 8-19.
17. Aubert M, Rice SA, Blaho JA. Accumulation of herpes simplex virus type 1 early and leaky-late proteins correlates with apoptosis prevention in infected human HEp-2 cells. J Virol 2001; 75: 1013-1030.
18. Aubert M, Blaho JA. The herpes simplex virus type 1 regulatory protein ICP27 is required for the prevention of apoptosis in infected human cells. J Virol 1999; 73: 2803-2813.
19. Boshart M et al. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J 1984; 3: 1151-1157.
20. Schwarz E et al. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 1985; 314: 111-114.
21. Scheffner M, Munger K, Byrne JC, Howley PM. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci USA 1991; 88, 5523-5527.
22. Scheffner M et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63: 1129-1136.
23. Munger K et al. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J 1989; 8: 4099-4105.
24. Blaho JA, Aaronson SA. Convicting a human tumor virus: guilt by association? Proc Natl Acad Sci USA 1999; 96: 7619-7621.
25. Howley PM. Role of the human papillomaviruses in human cancer. Cancer Res 1991; 51: 5019s-5022s.
26. Laimins LA. The biology of human papillomaviruses: from warts to cancer. Infect Agents Dis 1993; 2: 74-86.
27. Villa LL. Human papillomaviruses and cervical cancer. Adv Cancer Res 1997; 71: 321-341.
28. Moore AE, Sabachewsky L, Toolan HW. Culture characteristics of four permanent lines of human cancer cells. Cancer Res 1955; 15: 598-605.
29. Rhim JS, Cho HY, Huebner RJ. Non-producer human cells induced by murine sarcoma virus. Int J Cancer 1975; 15: 23-29.
30. Bacchetti S, Graham FL. Transfer of the gene for thymidine kinase to thymidine kinase-deficient human cells by purified herpes simplex viral DNA. Proc Natl Acad Sci USA 1977; 74: 1590-1594.
31. Kahn T, Schwarz E, zur Hausen H. Molecular cloning and characterization of the DNA of a new human papillomavirus (HPV 30) from a laryngeal carcinoma. Int J Cancer 1986; 37: 61-65.
32. Lu H, Taya Y, Ikeda M, Levine AJ. Ultraviolet radiation, but not gamma radiation or etoposide-induced DNA damage, results in the phosphorylation of the murine p53 protein at serine-389. Proc Natl Acad Sci USA 1998; 95: 6399-6402.
33. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977; 36: 59-74.
34. Lowe SW, Ruley HE. Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Dev 1993; 7: 535-545.
35. Preston CM, Rinaldi A, Nicholl MJ. Herpes simplex virus type 1 immediate early gene expression is stimulated by inhibition of protein synthesis. J Gen Virol 1998; 79: 117-124.
36. Debbas M, White E. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev 1993; 7: 546-554.
37. Leopardi R, Roizman B. The herpes simplex virus major regulatory protein ICP4 blocks apoptosis induced by the virus or by hyperthermia. Proc Natl Acad Sci USA 1996; 93: 9583-9587.
38. Koyama AH, Adachi A. Induction of apoptosis by herpes simplex virus type 1. J Gen Virol 1997; 78: 2909-2912.
39. Koyama AH, Miwa Y. Suppression of apoptotic DNA fragmentation in herpes simplex virus type 1-infected cells. J Virol 1997; 71: 2567-2571.
40. Jerome KR, Tait JF, Koelle DM, Corey L. Herpes simplex virus type 1 renders infected cells resistant to cytotoxic T-lymphocyte-induced apoptosis. J Virol 1998; 72: 436-441.
41. Galvan V, Roizman B. Herpes simplex virus 1 induces and blocks apoptosis at multiple steps during infection and protects cells from exogenous inducers in a cell-type-dependent manner. Proc Natl Acad Sci USA 1998; 95: 3931-3936.
42. Leopardi R, Van Sant C, Roizman B. The herpes simplex virus 1 protein kinase US3 is required for protection from apoptosis induced by the virus. Proc Nall Acad Sci USA 1997; 94: 7891-7896.
43. Jerome KR et al. Herpes simplex virus inhibits apoptosis through the action of two genes, Us5 and Us3. J Virol 1999; 73: 8950-8957.
44. Zhou G, Galvan V, Campadelli-Fiume G, Roizman B. Glycoprotein D or J delivered in trans blocks apoptosis in SK-N-SH cells induced by a herpes simplex virus 1 mutant lacking intact genes expressing both glycoproteins. J Virol 2000; 74: 11782-11791.
45. Fink DJ et al. Design and application of HSV vectors for neuroprotection. Gene Therapy 2000; 7: 115-119.
46. Goins WF et al. Development of replication-defective herpes simplex virus vectors. Methods Mol Med 2002; 69: 481-507.
47. Johnson PA et al. Cytotoxicity of a replication-defective mutant of herpes simplex virus type 1. J Virol 1992; 66: 2952-2965.
48. Huard J et al. LacZ gene transfer to skeletal muscle using a replication-defective herpes simplex virus type 1 mutant vector. Hum Gene Therapy 1997; 8: 439-452.
49. Samaniego LA, Webb AL, DeLuca NA. Functional interactions between herpes simplex virus immediate-early proteins during infection: gene expression as a consequence of ICP27 and different domains of ICP4. J Virol 1995; 69: 5705-5715.
50. Johnson PA, Wang MJ, Friedmann T. Improved cell survival by the reduction of immediate-early gene expression in replication-defective mutants of herpes simplex virus type 1 but not by mutation of the virion host shutoff function. J Virol 1994; 68: 6347-6362.
51. Holmes KD et al. A multi-mutant herpes simplex virus vector has minimal cytotoxic effects on the distribution of filamentous actin, alpha-actinin 2 and a glutamate receptor in differentiated PC12 cells. J Neurovirol 2000; 6: 33-45.
52. Krisky DM et al. Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Therapy 1998; 5: 1593-1603.
53. Moriuchi S et al. HSV vector cytotoxicity is inversely correlated with effective TK/GCV suicide gene therapy of rat gliosarcoma. Gene Therapy 2000; 7: 1483-1490.
54. Samaniego LA, Neiderhiser L, DeLuca NA. Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins. J Virol 1998; 72: 3307-3320.
55. Samaniego LA, Wu N, DeLuca NA. The herpes simplex virus immediate-early protein ICP0 affects transcription from the viral genome and infected-cell survival in the absence of ICP4 and ICP27. J Virol 1997; 71: 4614-4625.
56. Hobbs WE, Brough DE, Kovesdi I, DeLuca NA. Efficient activation of viral genomes by levels of herpes simplex virus ICP0 insufficient to affect cellular gene expression or cell survival. J Virol 2001; 75: 3391-3403.
57. Wu N, Watkins SC, Schaffer PA, DeLuca NA. Prolonged gene expression and cell survival after infection by a herpes simplex virus mutant defective in the immediate-early genes encoding ICP4, ICP27, and ICP22. J Virol 1996; 70: 6358-6369.
58. Lomonte P, Everett RD. Herpes simplex virus type 1 immediate-early protein Vmw110 inhibits progression of cells through mitosis and from G(1) into S phase of the cell cycle. J Virol 1999; 73: 9456-9467.
59. Hobbs II WE, DeLuca NA. Perturbation of cell cycle progression and cellular gene expression as a function of herpes simplex virus ICP0. J Virol 1999; 73: 8245-8255.
60. DeLuca NA, Courtney MA, Schaffer PA. Temperature-sensitive mutants in herpes simplex virus type 1 ICP4 permissive for early gene expression. J Virol 1984; 52: 767-776.
61. DeLuca NA, McCarthy AM, Schaffer PA. Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J Virol 1985; 56: 558-570.
62. DeLuca NA, Schaffer PA. Activation of immediate-early, early, and late promoters by temperature- sensitive and wild-type forms of herpes simplex virus type 1 protein ICP4. Mol Cell Biol 1985; 5: 1997-2208.
63. Knipe DM et al. Molecular genetics of herpes simplex virus. VI. Characterization of a temperature-sensitive mutant defective in the expression of all early viral gene products. J Virol 1981; 38: 539-547.
64. Preston CM. Control of herpes simplex virus type 1 mRNA synthesis in cells infected with wild-type virus or the temperature-sensitive mutant tsK. J Virol 1979; 29: 275-284.
65. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 2001; 7: 781-787.
66. Ganly I et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer [published erratum appears in Clin Cancer Res 2000 May;6(5):2120]. Clin Cancer Res 2000; 6: 798-806 (2000).
67. Khuri FR et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer [see comments]. Nat Med 2000; 6: 879-885.
68. Markert JM et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Therapy 2000; 7: 867-874.
69. Mineta T et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995; 1: 938-943.
70. Andreansky SS et al. The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc Natl Acad Sci USA 1996; 93: 11313-11318.
71. Chou J, Kern ER, Whitley RJ, Roizman B. Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 1990; 250: 1262-1266.
72. Raj K, Ogston P, Beard P. Virus-mediated killing of cells that lack p53 activity. Nature 2001; 412: 914-917.
73. Puck T, Marcus P, Cieciura SJ. Clonal growth of mammalian cells in vitro. J Exp Med 1956; 103: 273-284.
74. Post LE, Roizman B. A generalized technique for deletion of specific genes in large genomes: alpha gene 22 of herpes simplex virus 1 is not essential for growth. Cell 1981; 25: 227-232.
75. Yasumura Y, Kawakita Y. Nippon Rinsho 1963; 21: 1209.
76. Spector DJ. The pattern of integration of viral DNA sequences in the adenovirus 5-transformed human cell line 293. Virology 1983; 130: 533-538.
77. Hughes Jr RG, Munyon WH. Temperature-sensitive mutants of herpes simplex virus type 1 defective in lysis but not in transformation. J Virol 1975; 16: 275-283.
78. Soliman TM, Sandri-Goldin RM, Silverstein SJ. Shuttling of the herpes simplex virus type 1 regulatory protein ICP27 between the nucleus and cytoplasm mediates the expression of late proteins. J Virol 1997; 71: 9188-9197.